Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer

Clinical and Applied Thrombosis/Hemostasis

Volumn 18, Issue 2, 2012, Pages 159-165

  Haas, Sylvia K ^a   Freund, Mathias ^b   Heigener, David ^c   Heilmann, Lothar ^d   Kemkes Matthes, Bettina ^e   Tempelhoff, Georg Friedrich Von ^d   Melzer, Nima ^f   Kakkar, Ajay K ^g  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c KRANKENHAUS GROSSHANSDORF   (Germany)

^d Abteilung fur Gynakologie und Geburtshilfe   (Germany)

^e UNIVERSITY HOSPITAL GIESSEN   (Germany)

^f NOVARTIS PHARMA GMBH   (Germany)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

anticoagulants; deep venous thrombosis; low molecular weight heparins; thrombosis prophylaxis; venous thromboembolism

Indexed keywords

CERTOPARIN; LOW MOLECULAR WEIGHT HEPARIN; MONOEMBOLEX; PLACEBO;

ADULT; ARTICLE; BLEEDING; BREAST CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; DOUBLE-BLIND METHOD; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PULMONARY EMBOLISM; THROMBOCYTOPENIA; THROMBOPHILIA; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 84858421097     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029611433769     Document Type: Article

References (23)

1. Lee AY.. Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br J Haematol. 2005 ; 128 (3). 291-302 (Pubitemid 40216150)
2. Kakkar AK, Haas S, Wolf H, et al. Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy. Thromb Haemost. 2005 ; 94 (4). 867-871 (Pubitemid 41489251)
3. Kahn SR, Ducruet T, Lamping DL, et al. Prospective evaluation of health-related quality of life in patients with deep venous thrombosis. Arch Intern Med. 2005 ; 165 (10). 1173-1178 (Pubitemid 40720743)
4. Winter PC.. The pathogenesis of venous thromboembolism in cancer: emerging links with tumour biology. Hematol Oncol. 2006 ; 24 (3). 126-133 (Pubitemid 44483905)
5. Rickles FR, Falanga A.. Molecular basis for the relationship between thrombosis and cancer. Thromb Res. 2001 ; 102 (6). V215 - V224
6. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008 ; 111 (10). 4902-4907
7. Hall IE, Andersen MS, Krumholz HM, Gross CP.. Predictors of venous thromboembolism in patients with advanced common solid cancers. J Cancer Epidemiol. 2009 ; 2009: 182521
8. Mandalà M, Falanga A, Roila F.. Venous thromboembolism in cancer patients: ESMO clinical practice guidelines for the management. Ann Oncol. 2010 ; 21 (suppl 5). v274 - v276
9. Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005 ; 293 (6). 715-722 (Pubitemid 40216041)
10. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008 ; 133 (6 suppl). 381S - 453S (Pubitemid 351894916)
11. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double- blind randomized multicentre trial with venographic assessment. Br J Surg. 1997 ; 84: 1099-1103
12. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002 ; 346 (13). 975-980 (Pubitemid 34983247)
13. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994 ; 343 (8902). 886-889 (Pubitemid 24113632)
14. Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet. 2009 ; 10 (10). 943-949
15. Lyman GH, Khorana AA, Falanga A, et al. American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007 ; 25 (34). 5490-5505 (Pubitemid 350232226)
16. Verso M, Gussoni G, Agnelli G.. Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the PROTECHT and TOPIC-2 studies. J Thromb Haemost. 2010 ; 8 (7). 1649-1651
17. van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR.. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol. 2011 ; 29: 2071-2076
18. Borsig L.. Antimetastatic activities of heparins and modified heparins. Experimental evidence. Thromb Res. 2010 ; 125 (suppl. 2). S66 - S71
19. von Tempelhoff GF, Harenberg J, Niemann F, Hommel G, Kirkpatrick CJ, Heilmann L.. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol. 2000 ; 16 (4). 815-824
20. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002 ; 20 (21). 4319-4323 (Pubitemid 35266292)
21. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003 ; 21 (1). 60-65
22. Riess H, Pelzer U, Opitz B, et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: final results of the CONKO-004 trial. J Clin Oncol. 2010 ; 28 ((suppl 15) ):
23. Marveyas A, Waters J, Roy R, et al. Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). Eur J Cancer Suppl. 2009 ; 7: 362